Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spyre Therapeutics Inc SYRE

Healthcare Biotechnology
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and... see more

Recent & Breaking News (NDAQ:SYRE)

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire April 1, 2024

Spyre Therapeutics Announces $180 Million Private Placement

PR Newswire March 18, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire March 1, 2024

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PR Newswire February 29, 2024

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

PR Newswire February 26, 2024

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

PR Newswire February 8, 2024

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

PR Newswire February 5, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire February 2, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire December 22, 2023

Spyre Therapeutics Announces $180 Million Private Placement

PR Newswire December 7, 2023